Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$61.55

1.41 (2.34%)

, NBIX

Neurocrine

$44.59

2.29 (5.41%)

09:02
10/19/16
10/19
09:02
10/19/16
09:02

AbbVie reports 'positive' Phase 3 data from Elagolix trials

AbbVie (ABBV) in cooperation with Neurocrine Biosciences (NBIX) announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. The results were presented at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo in Salt Lake City, as well as additional abstracts. In the two studies, both doses of Elagolix administered orally demonstrated a statistically significant (p less than or equal to 0.001) improvement versus placebo in the percentage of DYS and NMPP responders. In the first study, at month three, 46 percent of patients treated with 150 mg once daily and 76 percent of patients treated with 200 mg twice daily of Elagolix were classified as DYS responders, versus 20 percent of patients in the placebo group. Fifty percent of patients treated with 150 mg once daily and 55 percent of patients treated with 200 mg twice daily of Elagolix were classified as NMPP responders, versus 36 percent of patients in the placebo group. The second pivotal Phase 3 study demonstrated similar results.

ABBV

AbbVie

$61.55

1.41 (2.34%)

NBIX

Neurocrine

$44.59

2.29 (5.41%)

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 28

    Oct

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

  • 14

    Dec

ABBV AbbVie
$61.55

1.41 (2.34%)

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/18/16
LEER
10/18/16
INITIATION
Target $70
LEER
Market Perform
AbbVie initiated with a Market Perform at Leerink
Leerink analyst Geoffrey Porges started AbbVie with a Market Perform rating and $70 price target. The analyst sees "significant uncertainty" about the durability of the company's dominant franchise, Humira.
NBIX Neurocrine
$44.59

2.29 (5.41%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/13/16
BMOC
10/13/16
NO CHANGE
BMOC
Neurocrine recent weakness unwarranted, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that Neurocrine (NBIX) has been weak recently in the wake of Myovant's S-1 filing. According to the analyst, investors view Myovant's relugolix as a more convenient alternative to Neurocrine's elagolix. However, the analyst thinks that relugolix's longer half-life "could complicate add-back therapy," while the wording of the questionnaire for relugolix's Phase 3 trial increases endometriosis clinical development risk. Additionally, the analyst says that Neurocrine's elagolix has a two to three year lead time over relugolix, setting the stage for both drugs to do well. He keeps a $66 price target and Outperform rating on Neurocrine.
10/18/16
NEED
10/18/16
INITIATION
Target $62
NEED
Buy
Neurocrine initiated with a Buy at Needham
Needham analyst Alan Carr initiated Neurocrine with a Buy and a $62 price target.

TODAY'S FREE FLY STORIES

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

07:37
09/22/17
09/22
07:37
09/22/17
07:37
Conference/Events
Federal Reserve Bank of Kansas City President to speak at conference »

Kansas City Federal…

MYGN

Myriad Genetics

$33.61

0.1 (0.30%)

07:36
09/22/17
09/22
07:36
09/22/17
07:36
Recommendations
Myriad Genetics analyst commentary  »

Myriad Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:35
09/22/17
09/22
07:35
09/22/17
07:35
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.41

-0.33 (-2.40%)

, MSFT

Microsoft

$74.21

-0.73 (-0.97%)

07:35
09/22/17
09/22
07:35
09/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AMD

AMD

$13.41

-0.33 (-2.40%)

MSFT

Microsoft

$74.21

-0.73 (-0.97%)

INTC

Intel

$37.20

0.13 (0.35%)

ABBV

AbbVie

KMI

Kinder Morgan

$19.32

-0.45 (-2.28%)

GLNG

Golar LNG

$21.34

0.19 (0.90%)

HAS

Hasbro

$94.84

-0.68 (-0.71%)

MIK

Michaels

$21.38

-0.04 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

  • 05

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:34
09/22/17
09/22
07:34
09/22/17
07:34
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRX

Agile Therapeutics

$3.77

0.04 (1.07%)

07:34
09/22/17
09/22
07:34
09/22/17
07:34
Initiation
Agile Therapeutics initiated  »

Agile Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Dec

SECO

Seeco Holding

07:33
09/22/17
09/22
07:33
09/22/17
07:33
Syndicate
Seeco Holding 8.5M share IPO priced at $13.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

AAXN

Axon

$22.80

-0.11 (-0.48%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Hot Stocks
Axon receives multiple orders for TASER X26P, TASER X2 smart weapons »

Axon announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$35.91

-0.06 (-0.17%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Recommendations
Micron analyst commentary  »

Micron's November…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

FGP

Ferrellgas Partners LP

$5.02

-0.13 (-2.52%)

, MDU

MDU Resources

$26.21

-0.19 (-0.72%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Hot Stocks
Ferrellgas Partners LP appoints Doran Schwartz as CFO »

Ferrellgas Partners L.P.…

FGP

Ferrellgas Partners LP

$5.02

-0.13 (-2.52%)

MDU

MDU Resources

$26.21

-0.19 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FINL

Finish Line

$9.22

-0.21 (-2.23%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Technical Analysis
Technical View: Finish Line drops after earnings and outlook »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

PANW

Palo Alto Networks

$140.06

-1.69 (-1.19%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Conference/Events
Palo Alto Networks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 07

    Dec

  • 11

    Dec

QCOM

Qualcomm

$52.03

0.05 (0.10%)

, NXPI

NXP Semiconductors

$112.72

0.17 (0.15%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Hot Stocks
Qualcomm extends cash tender offer for shares of NXP Semiconductors »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$52.03

0.05 (0.10%)

NXPI

NXP Semiconductors

$112.72

0.17 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

, TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Hot Stocks
Breaking Hot Stocks news story on Sprint, T-Mobile »

Sprint up 2.6% after…

S

Sprint

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

AZN

AstraZeneca

$32.81

-0.12 (-0.36%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Upgrade
AstraZeneca rating change  »

AstraZeneca upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 08

    Nov

SXT

Sensient

$75.90

0.19 (0.25%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Initiation
Sensient initiated  »

Sensient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

, CAR

Avis Budget

$38.08

0.16 (0.42%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

MRVL

Marvell

CAR

Avis Budget

$38.08

0.16 (0.42%)

GIS

General Mills

$51.69

-0.48 (-0.92%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

HOG

Harley-Davidson

$47.96

-0.39 (-0.81%)

JBLU

JetBlue

$18.90

-0.35 (-1.82%)

MXWL

Maxwell

$4.97

-0.155 (-3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 05

    Oct

  • 17

    Oct

  • 08

    Nov

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
T-Mobile, Sprint close to agreeing on deal terms, Reuters reports »

T-Mobile (TMUS) and…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

EADSY

Airbus

$23.07

0.78 (3.50%)

, BA

Boeing

$256.04

0.58 (0.23%)

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
Turkish Airlines mulls Airbus order following Boeing deal, Reuters reports »

Turkish Airlines has…

EADSY

Airbus

$23.07

0.78 (3.50%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Hot Stocks
Trump says greatest influence over election was 'Fake News Media' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:27
09/22/17
09/22
07:27
09/22/17
07:27
Periodicals
Breaking Periodicals news story on T-Mobile, Sprint, Deutsche Telekom, SoftBank »

T-Mobile, Sprint close to…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

FB

Facebook

$171.11

-1.06 (-0.62%)

07:26
09/22/17
09/22
07:26
09/22/17
07:26
Hot Stocks
Trump says Russia 'hoax' now onto Facebook ads »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

07:25
09/22/17
09/22
07:25
09/22/17
07:25
General news
FX Update: »

FX Update: USD-JPY dove…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.